63 The analysis of the group of metastatic patients followed the same trend but did not reach statistical significance. 64 A Phase II study undertaken by the EORTC Soft Tissue and Bone Sarcoma Group did not show responses in patients with STS. 65 Given the infancy of these tumor microenvironment-modifying agents in clinical studies, we will not include them in our review.
← all excerpts
Targeted therapy for soft tissue sarcomas in adolescents and young adults.
1
—
—